VERAXA Biotech Advances Monoclonal Antibody, ADC and BiTAC Programs for Solid Tumors
VRXA•VERAXA Biotech is advancing a pipeline of monoclonal antibodies, antibody-drug conjugates, bispecific ADCs and proprietary BiTAC-based T-cell engagers across multiple solid tumor indications. Its patented BiTAC platform aims to enable dual-targeting ADCs and TCEs with improved precision and safety in two rapidly growing oncology segments.
1. Diversified Antibody-Based Pipeline
VERAXA is developing a portfolio of antibody-based therapeutics including monoclonal antibodies, conventional ADCs, bispecific ADCs and T-cell engagers across multiple solid tumor indications.
2. Patented BiTAC Dual-Targeting Technology
Its proprietary BiTAC platform underpins dual-targeting ADCs and bispecific T-cell engager formats designed to improve treatment precision, enhance safety profiles and boost therapeutic effectiveness.
3. Strategic Positioning in Oncology Market
By focusing on conditionally active ADC and TCE technologies, the company targets two high-growth segments in the global oncology market and is advancing its lead programs toward clinical development.
